NO20020885L - <alfa>v<beta>3-integrininhibitorer - Google Patents

<alfa>v<beta>3-integrininhibitorer

Info

Publication number
NO20020885L
NO20020885L NO20020885A NO20020885A NO20020885L NO 20020885 L NO20020885 L NO 20020885L NO 20020885 A NO20020885 A NO 20020885A NO 20020885 A NO20020885 A NO 20020885A NO 20020885 L NO20020885 L NO 20020885L
Authority
NO
Norway
Prior art keywords
integrin
beta
alpha
xyz
solvates
Prior art date
Application number
NO20020885A
Other languages
English (en)
Other versions
NO20020885D0 (no
Inventor
Alfred Jonczyk
Oliver Schadt
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20020885D0 publication Critical patent/NO20020885D0/no
Publication of NO20020885L publication Critical patent/NO20020885L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Oppfinnelsen beskriver nye for- bindelser med formel (I): X-Y-Z-R1-CH2- R2 (R4)-CH2-CO-R5, som er biologisk aktive som ligander for integrinet avB3, hvor X, Y, Z, R1 R4 og R5 har de i krav l angitte betydninger, samt deres fysiologisk akseptable salter og solvater.
NO20020885A 1999-08-24 2002-02-22 <alfa>v<beta>3-integrininhibitorer NO20020885L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19939980A DE19939980A1 (de) 1999-08-24 1999-08-24 Inhibitoren des Integrins alphavbeta¶3¶
PCT/EP2000/007590 WO2001014337A1 (de) 1999-08-24 2000-08-04 INHIBITOREN DES INTEGRINS αvβ¿3?

Publications (2)

Publication Number Publication Date
NO20020885D0 NO20020885D0 (no) 2002-02-22
NO20020885L true NO20020885L (no) 2002-02-22

Family

ID=7919342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020885A NO20020885L (no) 1999-08-24 2002-02-22 <alfa>v<beta>3-integrininhibitorer

Country Status (19)

Country Link
US (1) US6645991B1 (no)
EP (1) EP1206455A1 (no)
JP (1) JP2003507457A (no)
KR (1) KR20020086849A (no)
CN (1) CN1370146A (no)
AR (1) AR034692A1 (no)
AU (1) AU6992500A (no)
BR (1) BR0013502A (no)
CA (1) CA2382561A1 (no)
CZ (1) CZ2002525A3 (no)
DE (1) DE19939980A1 (no)
HK (1) HK1049667A1 (no)
HU (1) HUP0203212A3 (no)
MX (1) MXPA02001862A (no)
NO (1) NO20020885L (no)
PL (1) PL352987A1 (no)
SK (1) SK2272002A3 (no)
WO (1) WO2001014337A1 (no)
ZA (1) ZA200202284B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008696D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
DE10063173A1 (de) * 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
AU783516B2 (en) 2001-04-30 2005-11-03 Warner-Lambert Company Methods, kits and compositions for using pyrrole derivatives
WO2003034995A2 (en) * 2001-10-22 2003-05-01 The Scripps Research Institute Integrin targeting compounds
MXPA05013637A (es) * 2003-08-13 2006-02-24 Chiron Corp Inhibidores gsk-3 y usos de los mismos.
WO2005117954A2 (en) 2004-06-04 2005-12-15 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
WO2006111925A2 (en) * 2005-04-18 2006-10-26 Sloan-Kettering Institute For Cancer Research Inhibition of tumorigenesis by inhibition of a6b4 integrin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234936A (en) * 1991-10-24 1993-08-10 American Home Products Corporation Pyrimidocycloalkanes as a ii antagonists
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
EP0628559B1 (en) * 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
JP2000506538A (ja) * 1996-03-29 2000-05-30 ジー．ディー．サール アンド カンパニー メタ―置換フェニレン誘導体
WO1997036882A1 (en) 1996-04-03 1997-10-09 Takeda Chemical Industries, Ltd. Oxazole derivatives, their production and use
EA200000921A1 (ru) 1998-03-10 2001-04-23 Смитклайн Бичам Корпорейшн Антагонисты рецептора витронектина
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds

Also Published As

Publication number Publication date
ZA200202284B (en) 2003-08-27
WO2001014337A1 (de) 2001-03-01
HK1049667A1 (zh) 2003-05-23
EP1206455A1 (de) 2002-05-22
AU6992500A (en) 2001-03-19
HUP0203212A2 (hu) 2003-02-28
NO20020885D0 (no) 2002-02-22
CA2382561A1 (en) 2001-03-01
CZ2002525A3 (cs) 2002-05-15
SK2272002A3 (en) 2002-06-04
DE19939980A1 (de) 2001-03-01
KR20020086849A (ko) 2002-11-20
PL352987A1 (en) 2003-09-22
US6645991B1 (en) 2003-11-11
MXPA02001862A (es) 2002-10-23
CN1370146A (zh) 2002-09-18
JP2003507457A (ja) 2003-02-25
AR034692A1 (es) 2004-03-17
HUP0203212A3 (en) 2005-02-28
BR0013502A (pt) 2002-05-07

Similar Documents

Publication Publication Date Title
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
SE9904652D0 (sv) Novel Compounds
NO20065178L (no) Tienopyridinderivater
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
MXPA04007018A (es) Quinazolina(di)onas para control de plagas de invertebrados.
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
DE69818831D1 (de) Indolderivate als mcp-1 rezeptor antagonisten
BR0211805A (pt) Herbicidas
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
HK1048474A1 (en) Substituted thiene-3-yl-sulfonyl amino(thio)carbonyl-triazolin(thi)ones.
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
PT1191025E (pt) Cristais de lansoprazol
HUP0202876A2 (hu) Karboxipeptidáz U gátló új vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20040881L (no) Orale antidiabetes midler.
NO20020885L (no) &lt;alfa&gt;v&lt;beta&gt;3-integrininhibitorer
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
DK1077218T3 (da) Peptidomimetiske forbindelser omfattende RGD-sekvenser, som er nyttige som integrininhibitorer
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
NO20004273L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene
TR200302288T2 (tr) Terapi için yeni bileşikler ve metotlar.
CY1106396T1 (el) Γραμμικες ή κυκλικες ουριες, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τις πepιεχουν
TW200509795A (en) Insecticidal phthalamide derivatives
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
NO20020886L (no) Nye integrin- &lt;alfa&gt;v&lt;beta&gt;3-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application